MCID: OCL033
MIFTS: 31

Oculocerebral Syndrome with Hypopigmentation

Categories: Rare diseases, Eye diseases, Skin diseases, Fetal diseases, Oral diseases

Aliases & Classifications for Oculocerebral Syndrome with Hypopigmentation

MalaCards integrated aliases for Oculocerebral Syndrome with Hypopigmentation:

Name: Oculocerebral Syndrome with Hypopigmentation 53 49 69
Cross Syndrome 53 49 55 69
Kramer Syndrome 53 49
Oculocerebral Hypopigmentation Syndrome, Cross Type 55
Oculocerebral Hypopigmentation Syndrome Type Preus 69
Hypopigmentation Oculocerebral Syndrome Cross Type 49
Oculocerebral Hypopigmentation Syndrome 49

Characteristics:

OMIM:

53
Inheritance:
autosomal recessive


HPO:

31
oculocerebral syndrome with hypopigmentation:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Oculocerebral Syndrome with Hypopigmentation

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 2719Disease definitionOculocerebral hypopigmentation syndrome, Cross type is a rare congenital syndrome characterized by cutaneous and ocular hypopigmentation, various ocular anomalies (e.g. corneal and lens opacity, spastic ectropium, and/or nystagmus), growth deficiency, intellectual deficit and other progressive neurologic anomalies such as spastic tetraplegia, hyperreflexia, and/or athetoid movements. The clinical picture varies among patients and may also include other anomalies such as urinary tract abnormalities, Dandy-Walker malformations, and/or bilateral inguinal hernia.Visit the Orphanet disease page for more resources. Last updated: 2/29/2012

MalaCards based summary : Oculocerebral Syndrome with Hypopigmentation, also known as cross syndrome, is related to oculocerebral hypopigmentation syndrome of preus and acrodermatitis enteropathica, zinc-deficiency type, and has symptoms including ataxia, abnormality of extrapyramidal motor function and athetosis. The drugs Ertapenem and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and bone.

Wikipedia : 72 Cross–McKusick–Breen syndrome (also known as \"Cross syndrome\", \"hypopigmentation and... more...

Description from OMIM: 257800

Related Diseases for Oculocerebral Syndrome with Hypopigmentation

Diseases related to Oculocerebral Syndrome with Hypopigmentation via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 oculocerebral hypopigmentation syndrome of preus 12.4
2 acrodermatitis enteropathica, zinc-deficiency type 10.9
3 dilution, pigmentary 10.4
4 autism 9.6
5 williams-beuren syndrome 9.5

Graphical network of the top 20 diseases related to Oculocerebral Syndrome with Hypopigmentation:



Diseases related to Oculocerebral Syndrome with Hypopigmentation

Symptoms & Phenotypes for Oculocerebral Syndrome with Hypopigmentation

Symptoms via clinical synopsis from OMIM:

53
Neuro:
spasticity
mental retardation
athetoid movements
dandy-walker cyst

Skin:
hypopigmentation
silver-gray hair color

Growth:
growth retardation

Eyes:
ocular anomalies


Clinical features from OMIM:

257800

Human phenotypes related to Oculocerebral Syndrome with Hypopigmentation:

55 31 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 55 31 frequent (33%) Frequent (79-30%) HP:0001251
2 abnormality of extrapyramidal motor function 55 31 frequent (33%) Frequent (79-30%) HP:0002071
3 athetosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0002305
4 abnormal pyramidal signs 55 31 frequent (33%) Frequent (79-30%) HP:0007256
5 nystagmus 55 31 frequent (33%) Frequent (79-30%) HP:0000639
6 intellectual disability 55 31 hallmark (90%) Very frequent (99-80%) HP:0001249
7 spasticity 55 31 Frequent (79-30%) HP:0001257
8 hyperreflexia 55 31 frequent (33%) Frequent (79-30%) HP:0001347
9 eeg abnormality 55 31 frequent (33%) Frequent (79-30%) HP:0002353
10 inguinal hernia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000023
11 cataract 55 31 frequent (33%) Frequent (79-30%) HP:0000518
12 depressed nasal bridge 55 31 frequent (33%) Frequent (79-30%) HP:0005280
13 corneal opacity 55 31 frequent (33%) Frequent (79-30%) HP:0007957
14 short nose 55 31 frequent (33%) Frequent (79-30%) HP:0003196
15 microcephaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0000252
16 sensorineural hearing impairment 55 31 occasional (7.5%) Occasional (29-5%) HP:0000407
17 anteverted nares 55 31 frequent (33%) Frequent (79-30%) HP:0000463
18 short stature 55 31 hallmark (90%) Very frequent (99-80%) HP:0004322
19 abnormality of the eye 55 31 Frequent (79-30%) HP:0000478
20 abnormality of vision 55 31 frequent (33%) Frequent (79-30%) HP:0000504
21 spastic tetraplegia 55 31 frequent (33%) Frequent (79-30%) HP:0002510
22 anemia 55 31 frequent (33%) Frequent (79-30%) HP:0001903
23 abnormality of the thumb 55 31 occasional (7.5%) Occasional (29-5%) HP:0001172
24 thin skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0000963
25 dolichocephaly 55 31 frequent (33%) Frequent (79-30%) HP:0000268
26 limitation of joint mobility 55 31 frequent (33%) Frequent (79-30%) HP:0001376
27 microdontia 55 31 frequent (33%) Frequent (79-30%) HP:0000691
28 cryptorchidism 55 31 frequent (33%) Frequent (79-30%) HP:0000028
29 growth delay 55 31 Frequent (79-30%) HP:0001510
30 myopia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000545
31 hypopigmentation of hair 55 31 occasional (7.5%) Occasional (29-5%) HP:0005599
32 arachnodactyly 55 31 frequent (33%) Frequent (79-30%) HP:0001166
33 abnormality of the voice 55 31 occasional (7.5%) Occasional (29-5%) HP:0001608
34 narrow mouth 55 31 frequent (33%) Frequent (79-30%) HP:0000160
35 abnormality of the palate 55 31 hallmark (90%) Very frequent (99-80%) HP:0000174
36 aplasia/hypoplasia affecting the eye 55 31 frequent (33%) Frequent (79-30%) HP:0008056
37 dandy-walker malformation 55 31 occasional (7.5%) Occasional (29-5%) HP:0001305
38 abnormality of bone marrow cell morphology 55 31 occasional (7.5%) Occasional (29-5%) HP:0005561
39 choroideremia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001139
40 ectropion 55 31 frequent (33%) Frequent (79-30%) HP:0000656
41 ocular albinism 55 31 frequent (33%) Frequent (79-30%) HP:0001107
42 ureteral stenosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000071
43 abnormality of movement 55 Frequent (79-30%)
44 abnormality of the urinary system 55 Occasional (29-5%)
45 iris hypopigmentation 55 Occasional (29-5%)
46 hypopigmentation of the skin 31 HP:0001010
47 silver-gray hair 31 HP:0002218

Drugs & Therapeutics for Oculocerebral Syndrome with Hypopigmentation

Drugs for Oculocerebral Syndrome with Hypopigmentation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1752)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 137234-62-9 71616
4
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-48-6 2160
5
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
6
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
7
Perphenazine Approved Phase 4,Phase 2,Not Applicable 58-39-9 4748
8
Sucralfate Approved Phase 4 54182-58-0 0
9
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
11
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
12
Ramipril Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 87333-19-5 5362129
13
Ticlopidine Approved Phase 4,Phase 2,Phase 1,Not Applicable 55142-85-3 5472
14
Cimetidine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 51481-61-9 2756
15
Cyproheptadine Approved Phase 4,Phase 2 129-03-3 2913
16
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
17
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable 54-11-5 89594 942
18
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 54-31-9 3440
19
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-93-5 3639
20
Eplerenone Approved Phase 4,Phase 3 107724-20-9 443872 150310
21
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1952-01-7, 52-01-7 5833
22
Saxagliptin Approved Phase 4,Phase 3,Phase 1 361442-04-8 11243969
23
Capsaicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 404-86-4 1548943
24
Glimepiride Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 93479-97-1 3476
25
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1491-59-4 4636
26
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-42-7 6041
27
Ezetimibe Approved Phase 4 163222-33-1 150311
28
Glatiramer Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147245-92-9 3081884
29 Piracetam Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 7491-74-9
30
Cilostazol Approved, Investigational Phase 4,Early Phase 1 73963-72-1 2754
31
Piperacillin Approved Phase 4 66258-76-2 43672
32
Sulbactam Approved Phase 4 68373-14-8
33
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 4091 14219
34
Teriparatide Approved, Investigational Phase 4,Phase 2,Phase 1 52232-67-4 16133850
35
4-Aminopyridine Approved Phase 4,Phase 2,Phase 3 504-24-5 1727
36
Citalopram Approved Phase 4,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
37
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
38
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3,Not Applicable 13422-51-0 5460373 44475014 11953898
39
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
40
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
41
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 69-65-8 6251 453
42
Procaine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-46-1 4914
43
Ustekinumab Approved, Investigational Phase 4,Phase 3 815610-63-0
44
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 58-14-0 4993
45
Sulfadoxine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2447-57-6 17134
46
Lopinavir Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 192725-17-0 92727
47
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 155213-67-5 392622
48
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
49
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
50
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 138402-11-6 3749

Interventional clinical trials:

(show top 50) (show all 10000)

# Name Status NCT ID Phase Drugs
1 Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) Unknown status NCT01914367 Phase 4
2 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4 VSL#3
3 Safety of Ertapenem in Beta-lactam Allergic Patients. Unknown status NCT01159379 Phase 4 ertapenem
4 Voriconazole for IPA in Chinese Patients With COPD Unknown status NCT02234739 Phase 4 Voriconazole
5 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
6 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
7 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
8 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
9 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
10 Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS Unknown status NCT01543373 Phase 4
11 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
12 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
13 Cyproheptadine as an Appetite Stimulant Unknown status NCT01314989 Phase 4 Cyproheptadine;Sugar pill
14 Dapagliflozin in Type 1 Diabetes Unknown status NCT02211742 Phase 4 Dapagliflozin
15 The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers Unknown status NCT01526304 Phase 4
16 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
17 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status NCT00515021 Phase 4 Eplerenone (Morning vs. evening drug regimen)
18 Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp Unknown status NCT02386943 Phase 4 Sitagliptin;Saxagliptin;Blank control
19 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
20 Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects Unknown status NCT00258141 Phase 4 Rupatadine;Placebo
21 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
22 Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" Unknown status NCT01660386 Phase 4 Sitagliptin;Saxagliptin;Glimepiride;Blank control
23 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
24 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
25 A Clinical Study Comparing the Comfort of Three Commercially Available Contact Lenses Unknown status NCT02298400 Phase 4
26 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
27 Physiological Response to Heliox21 and Air O2 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
28 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
29 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
30 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4 fluticasone/ salmeterol;fluticasone
31 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
32 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
33 Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study. Unknown status NCT01914055 Phase 4
34 Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. Unknown status NCT01063608 Phase 4
35 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
36 Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture Unknown status NCT00829725 Phase 4
37 Effect of Dapagliflozine on Systemic and Renal Endothelial Function Unknown status NCT02501616 Phase 4 Metformin;Dapagliflozin
38 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
39 Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation Unknown status NCT00326729 Phase 4
40 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
41 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
42 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Unknown status NCT01500785 Phase 4 levosimendan;Vitamin B 12
43 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
44 A Clinical Study to Evaluate the Efficacy and Safety of HA IDF II Plus Versus HA IDF II in Nasolabial Fold Injection Unknown status NCT02340078 Phase 4
45 Prospective Evaluation of Stent Patency in Patients With Benign Biliary Obstruction of the Wing Biliary Stent (Viaduct™) Unknown status NCT01818050 Phase 4
46 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
47 Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery Unknown status NCT01548872 Phase 4 HTK solution;crystalloid cardioplegia solution
48 A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
49 Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp;Efficacy of suphladoxine/pyrimethamine as IPTp
50 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4 raltegravir

Search NIH Clinical Center for Oculocerebral Syndrome with Hypopigmentation

Genetic Tests for Oculocerebral Syndrome with Hypopigmentation

Anatomical Context for Oculocerebral Syndrome with Hypopigmentation

MalaCards organs/tissues related to Oculocerebral Syndrome with Hypopigmentation:

38
Skin, Eye, Bone, Bone Marrow

Publications for Oculocerebral Syndrome with Hypopigmentation

Articles related to Oculocerebral Syndrome with Hypopigmentation:

(show all 11)
# Title Authors Year
1
The behavioural phenotype of Potocki-Lupski syndrome: a cross-syndrome comparison. ( 29329513 )
2018
2
Sensory and motor differences in Autism Spectrum Conditions and developmental coordination disorder in children: A cross-syndrome study. ( 29408162 )
2018
3
Overlapping Phenotypes in Autism Spectrum Disorder and Developmental Coordination Disorder: A Cross-Syndrome Comparison of Motor and Social Skills. ( 27126816 )
2016
4
Cross syndrome comparison of sleep problems in children with Down syndrome and Williams syndrome. ( 23475007 )
2013
5
Anxiety and repetitive behaviours in autism spectrum disorders and williams syndrome: a cross-syndrome comparison. ( 21424863 )
2012
6
A cross-syndrome study of the development of holistic face recognition in children with autism, Down syndrome, and Williams syndrome. ( 19193384 )
2009
7
Oculocerebral syndrome with hypopigmentation (Cross syndrome): report of a new case. ( 1544218 )
1992
8
Oculocerebral syndrome with hypopigmentation (Cross syndrome): the mixed pattern of hair pigmentation as an important diagnostic sign. ( 1801851 )
1991
9
Oculocerebral syndrome with hypopigmentation (Cross syndrome). Report of two siblings born to consanguineous parents. ( 3191612 )
1988
10
Oculocerebral syndrome with hypopigmentation. ( 819056 )
1975
11
A new oculocerebral syndrome with hypopigmentation. ( 4959856 )
1967

Variations for Oculocerebral Syndrome with Hypopigmentation

Expression for Oculocerebral Syndrome with Hypopigmentation

Search GEO for disease gene expression data for Oculocerebral Syndrome with Hypopigmentation.

Pathways for Oculocerebral Syndrome with Hypopigmentation

GO Terms for Oculocerebral Syndrome with Hypopigmentation

Sources for Oculocerebral Syndrome with Hypopigmentation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....